Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition for treating respiratory disease

A technology for respiratory diseases and compositions, applied in the field of pharmaceutical compositions for asthma, can solve problems such as low systemic bioavailability and no use of glucocorticoids, and achieve the effects of less systemic adverse reactions and lower incidence of side effects

Active Publication Date: 2009-01-21
天津药业集团有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] ③Low systemic bioavailability at therapeutic doses
However, in the prior art, methylprednisolone acetate is only used as a glucocorticoid for the treatment of human skin inflammation, and there is no report that it is used as an inhaled glucocorticoid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition for treating respiratory disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Methylprednisolone Acetate 20g

[0044] Ethanol 750g

[0045] Propylene glycol 150g

[0046] Dichlorodifluoromethane 1500g

[0047] Preparation process: add the prescribed amount of methylprednisolone acetate into ethanol and propylene glycol, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, seal the dose valve system, and then Pressurize and inject dichlorodifluoromethane to obtain the product, theoretically fill 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. Each bottle is 50 presses, and each press contains 400 μg of methylprednisolone acetate.

Embodiment 2

[0049] Methylprednisolone 12.5g

[0050] Ethanol 200g

[0051] Glycerol 19.5g

[0052] HFA227 750g

[0053] HFA134a 750g

[0054] Vitamin C 7.5g

[0055] Preparation process: Add the prescribed amount of methylprednisolone acetate into the vitamin C, ethanol and glycerol that are evenly stirred, stir, heat in a warm water bath to dissolve the raw materials, filter with a sand core funnel, fill in divided doses, and seal Dosage valve system, pressurize HFA134a and HFA227 respectively, to obtain, theoretically canned 1000 bottles, and the filling yield is above 85%. After 30 minutes of leak detection in a water bath at 45-50°C, there is no leakage. 50 presses per bottle, each press contains 250 μg of promethylprednisolone acetate

Embodiment 3

[0057] The active ingredient was changed to 15.75 g of methylprednisolone acetate, and other ingredients were prepared according to Example 2 to obtain a composition of 315 μg per press (equivalent to 250 μg of methylprednisolone)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating respiratory disease, in particular asthma and chronic obstructive pulmonary disease (COPD), especially asthma.

Description

technical field [0001] The invention provides a pharmaceutical composition for treating respiratory diseases, especially asthma, especially chronic obstructive pulmonary disease (COPD), especially asthma. Background technique [0002] Asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway responsiveness. Airway obstruction is caused by two factors: increased secretions caused by bronchial mucosal inflammation, mucosal edema, and smooth muscle spasm stimulated by inflammation; while asthma Increased airway reactivity is also a result of damage to the bronchial epithelium due to airway inflammation. It is recognized that only by controlling the inflammation of the airway mucosa can the ultimate goal of reducing airway hyperresponsiveness and relieving asthma symptoms be achieved. [0003] Asthma is a chronic airway inflammation characterized by reversible airway obstruction and increased airway responsiveness. Airway obstru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/573A61K9/12A61K47/26A61K47/18A61K47/10A61P11/06A61P11/02A61P11/00
Inventor 郝于田张乐陈松杨新意
Owner 天津药业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com